Pharma-Bio Serv, Inc. (PBSV) Jun 2024 Earnings Report
Pharma-Bio Serv, Inc. (PBSV): Investment Report
Overview
Pharma-Bio Serv, Inc. (PBSV) is a compliance and technology transfer services consulting firm operating in Puerto Rico, the United States, Europe, Brazil, and internationally. With a market capitalization of $15.61 million, PBSV provides technical compliance consulting services to the pharmaceutical, chemical manufacturing, biotechnology, medical device, cosmetic, food industries, and allied products companies. As a specialized player in the healthcare sector, PBSV has been consistently performing well, making it an attractive opportunity for investors. In this report, we will delve into the company's financial performance, growth prospects, and recent news to provide a comprehensive analysis of PBSV's investment potential.
Core Metrics
- Current price: $0.68 USD
- 52-week high: $1.10
- 52-week low: $0.52
- Market Cap: $15.61 million
- P/E Ratio: 22.67
- Earnings per Share: $0.03
- 50-day average: $0.7192
- 200-day average: $0.87895
- Analyst Recommendations: None (1 analyst opinion)
Financial Performance
Pharma-Bio Serv, Inc. has been consistently generating revenue, with a revenue growth rate of -0.438. The company's gross margins stand at 0.28851, and EBITDA margins are at 0.02578. The total cash available is $15.89 million, with a free cash flow of $4.035 million and an operating cash flow of $1.741 million. The company's EPS is $0.03, with a P/E ratio of 22.67.
Growth Prospects
PBSV's strong track record of providing technical compliance consulting services to the pharmaceutical and allied industries positions it for future growth. The company's expertise in compliance, project management, and technology transfer support consulting is likely to remain in demand, driving revenue growth. With an EBITDA margin of 0.02578, PBSV has room to improve its profitability, which could lead to increased earnings and a higher stock price.
News and Updates
Recent news articles highlight PBSV's consistent performance and impressive dividend yield. The company announced its 2Q 2023 results, which showed earnings per share of $0.02, in line with estimates. Pharma-Bio Serv also announced its results for the quarter ended April 30, 2024, demonstrating its ability to generate revenue and maintain profitability.
Upgrades and Downgrades
There have been no recent upgrades or downgrades for PBSV.
Summary
In conclusion, Pharma-Bio Serv, Inc. (PBSV) presents an attractive investment opportunity due to its consistent performance, impressive dividend yield, and strong growth prospects. With a market capitalization of $15.61 million, PBSV offers a unique value proposition for investors seeking exposure to the healthcare sector. However, investors should carefully consider the company's revenue growth rate and profitability margins before making an investment decision.
Disclosures
The information on this website should not be construed as or relied upon in any manner as investment, legal, tax, or other advice. You should consult your own advisers as to legal, business, tax, and other related matters concerning any investment. Any projections, estimates, forecasts, targets, prospects and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Any charts provided here or on other content distribution outlets are for informational purposes only, and should not be relied upon when making any investment decision. Under no circumstances should any information provided on this website or social media platforms be construed as an offer soliciting the purchase or sale of any security, nor should it be construed as an offer to provide investment advisory services.